Indivior Pharmaceuticals, Inc. Common Stock (INDV) Stock
NASDAQ · INDV
34.88
Fundamentals
Market cap
$4.12B
Price / Earnings ratio
11.9x
Price / Sales ratio
3.2x
Price / Book ratio
-20.3x
Return on assets
0.2%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Indivior Pharmaceuticals, Inc. Common Stock
Indivior, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees827
CEOMr. Joseph J. Ciaffoni
IPO DateDec 29, 2014
HeadquartersNorth Chesterfield, VA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph J. Ciaffoni | CEO & Director | 1971 |
| Mr. Ryan Preblick | Chief Financial Officer | 1976 |
| Dr. Christian Heidbreder | Chief Scientific Officer | 1963 |
| Mr. Jeffrey W. Burris J.D. | Chief Legal Officer | 1972 |
| Mr. Patrick a. Barry | Chief Commercial Officer | 1968 |
| Mr. Jason Thompson | Vice President of Investor Relations | — |
| Mr. Kevin L. Espinoza | Chief Integrity & Compliance Officer | — |
| Ms. Angela Colon-Mahoney M.S. | Chief Human Resources Officer | 1976 |
| Ms. Vanessa Procter | Executive Vice President of Corporate Affairs | — |
| Dr. Ann Wheeler Pharm.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Market cap$4.12B
Price-to-sales ratio3.16
Price-to-book value-20.25
Price-earnings ratio11.90
Return on Equity-142.00%
Return on Sales0.26%
Return on Assets0.19%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$2.88
Income Statement
Average volume2,021,333
EBITDA$354.00M
1 year high (52w)$42.81
1 year low (52w)$22.22
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



